{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:03:41Z","timestamp":1782504221337,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myeloid Derived Suppressor Cells (MDSCs) play important roles in constituting the immune suppressive environment promoting cancer development and progression. They are consisted of a heterogeneous population of immature myeloid cells including polymorphonuclear MDSC (PMN-MDSC) and monocytes MDSC (M-MDSC) that are found in both the systemic circulation and in the tumor microenvironment (TME). While previous studies had shown that all-trans retinoic acid (ATRA) could induce MDSC differentiation and maturation, the very poor solubility and fast metabolism of the drug limited its applications as an immune-modulator for cancer immunotherapy. We aimed in this study to develop a drug encapsulated liposome formulation L-ATRA with sustained release properties and examined the immuno-modulation effects. We showed that the actively loaded L-ATRA achieved stable encapsulation and enabled controlled drug release and accumulation in the tumor tissues. <jats:italic>In vivo<\/jats:italic> administration of L-ATRA promoted the remodeling of the systemic immune homeostasis as well as the tumor microenvironment. They were found to promote MDSCs maturation into DCs and facilitate immune responses against cancer cells. When used as a single agent treatment, L-ATRA deterred tumor growth, but only in immune-competent mice. In mice with impaired immune functions, L-ATRA at the same dose was not effective. When combined with checkpoint inhibitory agents, L-ATRA resulted in greater anti-cancer activities. Thus, L-ATRA may present a new IO strategy targeting the MDSCs that needs be further explored for improving the immunotherapy efficacy in cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2022.829391","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T07:16:30Z","timestamp":1649747790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment"],"prefix":"10.3389","volume":"13","author":[{"given":"Anjie","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shounan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-Derived Suppressor Cells as Regulators of the Immune System","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122264","article-title":"Global Immune Fingerprinting in Glioblastoma Patient Peripheral Blood Reveals Immune-Suppression Signatures Associated With Prognosis","volume":"3","author":"Alban","year":"2018","journal-title":"JCI Insight"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The Tumor Microenvironment is a Dominant Force in Multidrug Resistance","volume":"15","author":"Correia","year":"2012","journal-title":"Drug Resist Updates"},{"key":"B5","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Trans Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1396-8","article-title":"Therapeutic Regulation of Myeloid-Derived Suppressor Cells and Immune Response to Cancer Vaccine in Patients With Extensive Stage Small Cell Lung Cancer","volume":"62","author":"Iclozan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of Circulating MDSC Correlate With Clinical Outcome of Melanoma Patients Treated With Ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid Derived Suppressor Cells\u2013a New Therapeutic Target in the Treatment of Cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1690","article-title":"All-Trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients","volume":"66","author":"Mirza","year":"2006","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the Tumor Microenvironment: Removing Obstruction to Anticancer Immune Responses and Immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"B11","article-title":"All-Trans-Retinoic Acid Eliminates Immature Myeloid Cells From Tumor-Bearing Mice and Improves the Effect of Vaccination","volume":"63","author":"Kusmartsev","year":"2003","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.08.007","article-title":"Targeting Myeloid-Derived Suppressor Cells Using All-Trans Retinoic Acid in Melanoma Patients Treated With Ipilimumab","volume":"63","author":"Tobin","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0003-9861(91)90482-X","article-title":"Solubility of Retinoids in Water","volume":"287","author":"Szuts","year":"1991","journal-title":"Arch Biochem Biophysics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/neu.20242","article-title":"Overview of Retinoid Metabolism and Function","volume":"66","author":"Blomhoff","year":"2006","journal-title":"J Neurobiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11671-020-3293-3","article-title":"Co-Delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma","volume":"15","author":"Li","year":"2020","journal-title":"Nanoscale Res Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080707","article-title":"Current Trends in ATRA Delivery for Cancer Therapy","volume":"12","author":"Giuli","year":"2020","journal-title":"Pharmaceutics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.10.019","article-title":"All-Trans Retinoic Acid Stealth Liposomes Prevent the Relapse of Breast Cancer Arising From the Cancer Stem Cells","volume":"149","author":"Li","year":"2011","journal-title":"J Controlled Release"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.7150\/thno.19987","article-title":"Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency","volume":"7","author":"Kong","year":"2017","journal-title":"Theranostics"},{"key":"B19","first-page":"292","article-title":"Pharmacokinetics of Intravenously Administered Liposomal All-Trans-Retinoic Acid (ATRA) and Orally Administered ATRA in Healthy Volunteers","volume":"6","author":"Ozpolat","year":"2003","journal-title":"J Pharm Pharm Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fphar.2019.00447","article-title":"Synergistic Effect of Retinoic Acid Polymeric Micelles and Prodrug for the Pharmacodynamic Evaluation of Tumor Suppression","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2016.11677","article-title":"Improved In Vitro Antileukemic Activity of All-Trans Retinoic Acid Loaded in Cholesteryl Butyrate Solid Lipid Nanoparticles","volume":"16","author":"Silva","year":"2016","journal-title":"J Nanosci Nanotechnol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3839","article-title":"Active Pin1 is a Key Target of All-Trans Retinoic Acid in Acute Promyelocytic Leukemia and Breast Cancer","volume":"21","author":"Wei","year":"2015","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/jcm9020360","article-title":"Retinoic Acids in the Treatment of Most Lethal Solid Cancers","volume":"9","author":"Costantini","year":"2020","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3415","article-title":"Blockade of Myeloid-Derived Suppressor Cell Expansion With All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy","volume":"78","author":"Bauer","year":"2018","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs With All-Trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2020.02.042","article-title":"Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression","volume":"180","author":"Devalaraja","year":"2020","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.V79.2.299.bloodjournal792299","article-title":"Continuous Treatment With All-Transretinoic Acid Causes a Progressive Reduction in Plasma Drug Concentrations: Implications for Relapse and Retinoid \u201cResistance\u201d in Patients With Acute Promyelocytic Leukemia","volume":"79","author":"Muindi","year":"1992","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(94)90040-X","article-title":"Liposome Encapsulation Circumvents the Hepatic Clearance Mechanisms of All-Trans-Retinoic Acid","volume":"18","author":"Mehta","year":"1994","journal-title":"Leukemia Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1646","article-title":"Differences in the Lipoprotein Distribution of Free and Liposome-Associated All-Trans-Retinoic Acid in Human, Dog, and Rat Plasma are Due to Variations in Lipoprotein Lipid and Protein Content","volume":"42","author":"Wasan","year":"1998","journal-title":"Antimicrobial Agents Chemother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2011.566552","article-title":"Active Methods of Drug Loading Into Liposomes: Recent Strategies for Stable Drug Entrapment and Increased In Vivo Activity","volume":"8","author":"Gubernator","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.7b01235","article-title":"Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance","volume":"3","author":"Wei","year":"2018","journal-title":"ACS Omega"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26896","article-title":"Circulating Myeloid-Derived Suppressor Cells: An Independent Prognostic Factor in Patients With Breast Cancer","volume":"234","author":"Safarzadeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e57114","DOI":"10.1371\/journal.pone.0057114","article-title":"Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients With Colorectal Carcinoma","volume":"8","author":"Zhang","year":"2013","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2863","article-title":"Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling","volume":"72","author":"Nagaraj","year":"2012","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4049\/jimmunol.1300654","article-title":"Reciprocal Relationship Between Myeloid-Derived Suppressor Cells and T Cells","volume":"191","author":"Nagaraj","year":"2013","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J Controlled Release"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1008371","DOI":"10.1080\/2162402X.2015.1008371","article-title":"Extracellular Vesicle-Mediated Transfer of Functional RNA in the Tumor Microenvironment","volume":"4","author":"Ridder","year":"2015","journal-title":"Oncoimmunology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1564505","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/Galectin-9 Pathway and mMDSC Control Primary and Secondary Resistances to PD-1 Blockade in Lung Cancer Patients","volume":"8","author":"Limagne","year":"2019","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.829391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T07:16:37Z","timestamp":1649747797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.829391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2022.829391"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.829391","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"829391"}}